Pharmaceutical Technology
MARCH 16, 2023
Talem Therapeutics, a subsidiary of Immunoprecise Antibodies, has entered a multi-target artificial intelligence (AI)-driven antibody discovery collaboration with Libera Bio. The MPN Technology provides an elegant way for delivering antibodies inside tumour cells.
Drug Discovery World
APRIL 3, 2023
From humble beginnings in the founder’s basement, UK-based Aptamer Group is now supplying its Optimer binders to clients across big pharma. As life science operates globally, the vision for the business was always to bring aptamers as an antibody alternative to researchers worldwide. To what do you attribute your success?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
OCTOBER 4, 2022
The company’s candidate screening approach recapitulates aspects of tau oligomer formation in neurodegenerative diseases and enables the identification of novel therapeutic approaches. Several of the large pharma companies have recently re-entered the dementia field. With its recent award of $3.35 Overcoming sector challenges
Drug Discovery World
NOVEMBER 16, 2022
DDW Editor Reece Armstrong learns about Molecular Devices’ Organoid Innovation Centre (OIC) and how the company is aiming to advance research into 3D biology and organoids. . Therefore, while researchers can understand just how a drug molecule impacts a cell, they can’t be sure that it will perform the same when used in-vivo. .
Drug Discovery World
FEBRUARY 2, 2024
Every company does their purification differently, every company does their sequencing slightly differently, every company does their assays slightly differently. It’s not fully standardised, so companies still do some boutique work. However, we’re still a couple of years early for general purpose AI in science.
XTalks
AUGUST 17, 2020
To learn more about innovations in the field, Xtalks spoke to Anish Suri, PhD, president and chief scientific officer of Cue Biopharma about the company’s initiatives in the development of immune-based biological compounds for the treatment of cancers and autoimmune diseases. Cell-Based Immunotherapy vs. Immune Biologics.
Drug Discovery World
NOVEMBER 15, 2022
Developed with the idea of engineering an enzyme called terminal deoxynucleotidyl transferase (TdT), a type of DNA polymerase, these enzymatic DNA synthesis methods are now the focus of dozens of companies. Anita Ramanathan outlines four synthetic biology approaches that are improving and accelerating drug discovery. .
Expert insights. Personalized for you.
262 
Let's personalize your content